Experimental drug aims to revive failing cancer fighters in rare sarcomas
NCT ID NCT07261657
First seen Dec 30, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This early study tests a drug called N-803 in 8 people with rare soft-tissue sarcomas (synovial sarcoma or myxoid/round cell liposarcoma) whose cancer grew after a prior cell therapy. N-803 is an immune-boosting protein that may help the body's remaining cancer-fighting cells work better. The main goals are to see if the drug is safe and whether it can make those persisting cells expand to attack the tumor again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.